GB268 / Edding Genor Group - LARVOL DELTA

First-in-human phase Ⅰ study of GB268, a tri-specific antibody targeting PD-1, CTLA-4 and VEGF, in patients with advanced solid tumors (ESMO 2026) - No abstract available

Clinical • First-in-human • Metastases • P1 data • Trispecific • Oncology • Solid Tumor

Edding Genor Group…is pleased to announce that the first subject dosing has been successfully completed on 5 August 2026 in the Phase Ib/II clinical trial of GB268…for the treatment of locally advanced unresectable or metastatic breast cancer, including triple-negative breast cancer (TNBC) and hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (HKEXnews) - "In the future, the Company also expects to initiate multiple combination therapy clinical studies in additional advanced solid tumor indications. The Phase I clinical data for GB268 monotherapy are planned to be presented at the European Society for Medical Oncology (ESMO) congress in the fourth quarter of 2026."

P1 data • Trial status • HER2 Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Triple Negative Breast Cancer

Edding Genor Wins NMPA Nod for Phase Ib/II Trial of Trispecific Breast Cancer Antibody GB268 (TipRanks) - "Edding Genor gained NMPA approval to launch a Phase Ib/II trial of its trispecific antibody GB268 in advanced metastatic breast cancer, exploring both monotherapy and combination regimens across multiple treatment lines."

New P1/2 trial • Breast Cancer • Oncology

Development of GB268, a tri-specific antibody targeting PD-1/CTLA-4/VEGF, with enhanced anti-tumor efficacy and reduced toxicity in pre-clinical studies (AACR 2024) - "Combined application of bevacizumab and PD-1/PD-L1 blockade displays durable and improved anti-tumor effects...In arthritis induction model using hPD1/hCTLA4 double KI mice, GB268 had improved tolerance than cadonilimab and at least 20-fold better safety profile than ipilimumab combined with nivolumab. GB268 is a first-in-class anti-PD-1/CTLA-4/VEGF tri-specific antibody with innovative design... GB268 is a first-in-class anti-PD-1/CTLA-4/VEGF tri-specific antibody with innovative design. Preclinical data demonstrated GB268 is very effective in provoking anti-tumor responses. At the meantime, immune-related AEs is alleviated."

IO biomarker • Preclinical • Trispecific • Cervical Cancer • Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD80 • CD86

A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=330 | Not yet recruiting | Sponsor: Genor Biopharma Co., Ltd.

New P1 trial • Oncology • Solid Tumor